KR102135818B1 - 강력한 ｔ-세포 및 항체 반응을 위한 ｐｒ13.5 프로모터 - Google Patents

강력한 ｔ-세포 및 항체 반응을 위한 ｐｒ13.5 프로모터 Download PDF

Info

Publication number
KR102135818B1
KR102135818B1 KR1020157009206A KR20157009206A KR102135818B1 KR 102135818 B1 KR102135818 B1 KR 102135818B1 KR 1020157009206 A KR1020157009206 A KR 1020157009206A KR 20157009206 A KR20157009206 A KR 20157009206A KR 102135818 B1 KR102135818 B1 KR 102135818B1
Authority
KR
South Korea
Prior art keywords
mva
promoter
virus
recombinant
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157009206A
Other languages
English (en)
Korean (ko)
Other versions
KR20150079596A (ko
Inventor
로빈 슈타이거발트
케이 브린크만
Original Assignee
버베리안 노딕 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버베리안 노딕 에이/에스 filed Critical 버베리안 노딕 에이/에스
Publication of KR20150079596A publication Critical patent/KR20150079596A/ko
Application granted granted Critical
Publication of KR102135818B1 publication Critical patent/KR102135818B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020157009206A 2012-10-28 2013-10-28 강력한 ｔ-세포 및 항체 반응을 위한 ｐｒ13.5 프로모터 Active KR102135818B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261719429P 2012-10-28 2012-10-28
US61/719,429 2012-10-28
PCT/EP2013/003239 WO2014063832A1 (en) 2012-10-28 2013-10-28 Pr13.5 promoter for robust t-cell and antibody responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207020263A Division KR20200087880A (ko) 2012-10-28 2013-10-28 강력한 ｔ-세포 및 항체 반응을 위한 ｐｒ13.5 프로모터

Publications (2)

Publication Number Publication Date
KR20150079596A KR20150079596A (ko) 2015-07-08
KR102135818B1 true KR102135818B1 (ko) 2020-07-22

Family

ID=49513897

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157009206A Active KR102135818B1 (ko) 2012-10-28 2013-10-28 강력한 ｔ-세포 및 항체 반응을 위한 ｐｒ13.5 프로모터
KR1020207020263A Ceased KR20200087880A (ko) 2012-10-28 2013-10-28 강력한 ｔ-세포 및 항체 반응을 위한 ｐｒ13.5 프로모터

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207020263A Ceased KR20200087880A (ko) 2012-10-28 2013-10-28 강력한 ｔ-세포 및 항체 반응을 위한 ｐｒ13.5 프로모터

Country Status (26)

Country Link
US (2) US9828414B2 (enExample)
EP (2) EP2912183B1 (enExample)
JP (2) JP6505016B2 (enExample)
KR (2) KR102135818B1 (enExample)
CN (1) CN104755622B (enExample)
AU (1) AU2013337018B2 (enExample)
BR (1) BR112015009320A2 (enExample)
CA (1) CA2887623C (enExample)
CY (1) CY1123181T1 (enExample)
DK (1) DK2912183T3 (enExample)
EA (2) EA201990114A1 (enExample)
ES (1) ES2800623T3 (enExample)
HK (1) HK1212383A1 (enExample)
HU (1) HUE049706T2 (enExample)
IL (1) IL238130B (enExample)
IN (1) IN2015DN03326A (enExample)
LT (1) LT2912183T (enExample)
MX (2) MX380483B (enExample)
MY (2) MY171687A (enExample)
NZ (1) NZ706637A (enExample)
PT (1) PT2912183T (enExample)
SG (2) SG11201503200PA (enExample)
SI (1) SI2912183T1 (enExample)
UA (1) UA118340C2 (enExample)
WO (1) WO2014063832A1 (enExample)
ZA (1) ZA201502892B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN03326A (enExample) * 2012-10-28 2015-10-09 Bavarian Nordic As
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
HUE059343T2 (hu) 2016-01-29 2022-11-28 Bavarian Nordic As Rekombináns, módosított Ankara Vaccinia vírus (MVA) és ló encephalitis vírus oltóanyag
WO2017192418A1 (en) 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
US11052139B2 (en) 2016-09-28 2021-07-06 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
JP7110203B2 (ja) 2016-12-28 2022-08-01 トランジェーヌ 腫瘍溶解性ウイルスおよび治療用分子
BR112019026126A2 (pt) 2017-06-15 2020-06-30 Janssen Vaccines & Prevention B.V. vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
BR112020003669A2 (pt) 2017-08-24 2020-09-01 Bavarian Nordic A/S terapia de combinação para tratamento do câncer com administração intravenosa de um mva recombinante e de um anticorpo
MX2020006471A (es) 2017-12-19 2020-09-22 Janssen Sciences Ireland Unlimited Co Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
GB201807932D0 (en) * 2018-05-16 2018-06-27 Redchenko Irina Compositions and methods for inducing an immune response
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
CN110904127B (zh) 2018-09-18 2024-09-20 瓦赫宁恩研究基金会 非洲猪瘟病毒疫苗
JP7555334B2 (ja) 2018-10-05 2024-09-24 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
JP7625518B2 (ja) 2018-11-20 2025-02-03 バヴァリアン・ノルディック・アクティーゼルスカブ ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法
EP4061406A1 (en) 2019-11-20 2022-09-28 Bavarian Nordic A/S Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
IL298834A (en) 2020-06-10 2023-02-01 Bavarian Nordic As A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
IL311078A (en) 2021-09-03 2024-04-01 Bavarian Nordic As Use of microRNA to downregulate expression of cytotoxic transgenes by modified vicinia ankara virus (mva)
EP4452305A1 (en) 2021-12-23 2024-10-30 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023118563A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Therapy for modulating immune response with recombinant mva encoding il-12
CN119630419A (zh) 2022-06-29 2025-03-14 巴法里安诺迪克有限公司 重组修饰的saRNA(VRP)和痘苗病毒安卡拉(MVA)初免-加强方案
TW202413636A (zh) 2022-08-18 2024-04-01 法商傳斯堅公司 嵌合痘病毒
WO2024149832A1 (en) 2023-01-12 2024-07-18 Bavarian Nordic A/S RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee
WO2025238220A1 (en) 2024-05-17 2025-11-20 Bavarian Nordic A/S Nucleic acids for vaccination encoding antigen-displaying protein nanoparticles
WO2025238218A1 (en) 2024-05-17 2025-11-20 Bavarian Nordic A/S Viral vectors encoding antigen-displaying protein nanoparticles
WO2025238221A1 (en) 2024-05-17 2025-11-20 Bavarian Nordic A/S Viral vectors encoding multi-antigen-displaying protein nanoparticles
WO2025238219A1 (en) 2024-05-17 2025-11-20 Bavarian Nordic A/S Modified vaccinia virus ankara (mva) encoding antigen-displaying protein nanoparticles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073431A2 (en) * 2004-06-25 2006-07-13 Merial Limited Avipox recombinants expressing foot and mouth disease virus genes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB9922361D0 (en) * 1999-09-21 1999-11-24 Isis Innovation Generating an immune response to an antigen
AU3163902A (en) 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
JP2008301792A (ja) 2007-06-11 2008-12-18 National Univ Corp Shizuoka Univ 改変ポリヘドリンプロモーター、バクミド変異体及び目的タンパク質の製造方法
AU2009319336B2 (en) 2008-11-27 2015-03-26 Bavarian Nordic A/S Promoters for recombinant viral expression
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
IN2015DN03326A (enExample) * 2012-10-28 2015-10-09 Bavarian Nordic As

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073431A2 (en) * 2004-06-25 2006-07-13 Merial Limited Avipox recombinants expressing foot and mouth disease virus genes

Also Published As

Publication number Publication date
MX2015005264A (es) 2015-07-17
PT2912183T (pt) 2020-06-05
KR20200087880A (ko) 2020-07-21
US20150299267A1 (en) 2015-10-22
IL238130A0 (en) 2015-05-31
DK2912183T3 (da) 2020-07-27
HUE049706T2 (hu) 2020-10-28
IL238130B (en) 2019-09-26
US11028130B2 (en) 2021-06-08
HK1212383A1 (en) 2016-06-10
MX2021001638A (es) 2021-05-12
JP2015533841A (ja) 2015-11-26
CN104755622B (zh) 2021-04-20
IN2015DN03326A (enExample) 2015-10-09
CY1123181T1 (el) 2021-10-29
CN104755622A (zh) 2015-07-01
EP2912183A1 (en) 2015-09-02
UA118340C2 (uk) 2019-01-10
CA2887623A1 (en) 2014-05-01
SG10201704657WA (en) 2017-07-28
EA201590831A1 (ru) 2015-08-31
US20180111966A1 (en) 2018-04-26
EA201990114A1 (ru) 2019-09-30
ZA201502892B (en) 2020-08-26
KR20150079596A (ko) 2015-07-08
JP6818797B2 (ja) 2021-01-20
AU2013337018A9 (en) 2018-08-30
EP2912183B1 (en) 2020-05-06
US9828414B2 (en) 2017-11-28
SI2912183T1 (sl) 2020-07-31
MX380483B (es) 2025-03-12
ES2800623T3 (es) 2021-01-04
EP3778904A1 (en) 2021-02-17
JP6505016B2 (ja) 2019-04-24
CA2887623C (en) 2021-02-16
MY171687A (en) 2019-10-23
WO2014063832A1 (en) 2014-05-01
BR112015009320A2 (pt) 2017-10-17
EA032498B1 (ru) 2019-06-28
NZ706637A (en) 2019-02-22
SG11201503200PA (en) 2015-05-28
MY194609A (en) 2022-12-06
AU2013337018B2 (en) 2019-09-05
AU2013337018A1 (en) 2015-04-30
LT2912183T (lt) 2020-07-27
JP2019131572A (ja) 2019-08-08

Similar Documents

Publication Publication Date Title
KR102135818B1 (ko) 강력한 ｔ-세포 및 항체 반응을 위한 ｐｒ13.5 프로모터
US8394385B2 (en) Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
EP2864487B1 (en) Poxviral vectors for low antibody response after a first priming immunization
US8613936B2 (en) Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
HK40044708A (en) Pr13.5 promoter for robust t-cell and antibody responses
AU2017228587B2 (en) Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines
DK2864487T3 (en) COPPER VIRUS VECTORS TO GET LOW ANTIBODY RESPONSE AFTER A FIRST PRIMING IMMUNIZATION
EA045254B1 (ru) Промотор pr13.5 для устойчивых т-клеточных и гуморальных иммунных реакций

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150409

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180813

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191120

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200416

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200713

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200714

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200714

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240625

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20250625

Start annual number: 6

End annual number: 6